Payment overview · 2025
General Payments
$291.91
16 reported records · 6 companies
Healthcare provider profile · identity verified
Michael Cory Campbell, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · HONESDALE, PA · NPI 1669684460
Verified facts
What the public records show
CMS Open Payments records show Michael Cory Campbell, MD received $291.91 in general payments during 2025 across 16 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 54.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Sublocade.
Indivior Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SUBLOCADE as an associated drug or biological on 22829 records involving 8874 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Sublocade by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $159.92 | 54.8% | 9 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $42.26 | 14.5% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $31.78 | 10.9% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $22.27 | 7.6% | 1 | 2025 |
| Sage Therapeutics, LLC | Unresolved — no canonical attribution shown | $20.50 | 7.0% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $15.18 | 5.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $291.91 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $112.41 | 6 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $47.51 | 3 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $42.26 | 2 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $35.13 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $22.27 | 1 | 2025 |
Source payment records
|
|||||
| ZURZUVAE Normalized: zurzuvae |
Drug | Sage Therapeutics, LLC | $20.50 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $16.58 | 1 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $15.20 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $15.18 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| SUBLOCADE sublocade |
2025 | Sublocade | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Indivior Inc. Exact reporting entity; no affiliate inference |
2025 | SUBLOCADE open payments reported associated product |
CMS Open Payments — General Payments 22829 supporting records · 8874 recipient NPIs · example record 1240470773 |
Sublocade · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clonazepam | Clonazepam | 150 | 20 |
| Trazodone Hcl | Trazodone Hcl | 120 | 26 |
| Sertraline Hcl | Sertraline Hcl | 104 | 16 |
| Diazepam | Diazepam | 97 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 97 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 87 | 17 |
| Lorazepam | Lorazepam | 87 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 86 | 16 |
| Buspirone Hcl | Buspirone Hcl | 83 | 13 |
| Lurasidone Hcl | Lurasidone Hcl | 82 | 12 |
| Bupropion Xl | Bupropion Hcl | 72 | 15 |
| Lamotrigine | Lamotrigine | 72 | 13 |
| Prazosin Hcl | Prazosin Hcl | 65 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 65 | suppressed |
| Mirtazapine | Mirtazapine | 64 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 56 | 11 |
| Benztropine Mesylate | Benztropine Mesylate | 51 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 48 | suppressed |
| Aripiprazole | Aripiprazole | 47 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 46 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 45 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 45 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 43 | suppressed |
| Topiramate | Topiramate | 43 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 42 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 41 | suppressed |
| Olanzapine | Olanzapine | 41 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 40 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 38 | suppressed |
| Perphenazine | Perphenazine | 38 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | 12 |
| Sublocade | Buprenorphine | 34 | suppressed |
| Clozapine | Clozapine | 33 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 33 | suppressed |
| Alprazolam | Alprazolam | 32 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 29 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 25 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 24 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 24 | suppressed |
| Carbamazepine | Carbamazepine | 22 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 22 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 22 | suppressed |
| Haloperidol | Haloperidol | 21 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Gabapentin | Gabapentin | 18 | suppressed |
| Ozempic | Semaglutide | 18 | suppressed |
| Paliperidone Er | Paliperidone | 18 | suppressed |
| Risperidone | Risperidone | 18 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Caplyta | Lumateperone Tosylate | 16 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 16 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 16 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 14 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 14 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 13 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 13 | suppressed |
| Latuda | Lurasidone Hcl | 13 | suppressed |
| Pindolol | Pindolol | 13 | suppressed |
| Thiothixene | Thiothixene | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 12 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 12 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $291.91 · 16 records | Otsuka America Pharmaceutical, Inc. | ABILIFY ASIMTUFII, ABILIFY MAINTENA, AUSTEDO XR, FANAPT, INGREZZA, REXULTI, SUBLOCADE, UZEDY, ZURZUVAE | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Sublocade play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Indivior Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error